Denosumab mid-term densitometric gain in postmenopausal osteoporosis women in clinical practice: comment on “Variability of denosumab densitometric response in postmenopausal osteoporosis”

• Published in: Rheumatology international Vol. 38; no. 6; pp. 1161 - 1162
• Main Authors: Torrente-Segarra, V., Roig-Vilaseca, D.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-06-2018; Springer Nature B.V
• Subjects: Aged; Bone Density; Bone Density Conservation Agents - therapeutic use; Clinical medicine; Correspondence; Denosumab - therapeutic use; Female; Humans; Medicine; Medicine & Public Health; Monoclonal antibodies; Osteoporosis; Osteoporosis, Postmenopausal - drug therapy; Osteoporotic Fractures; Rheumatology; Denosumab; Osteoporosis; Bone mineral density
• ISSN: 0172-8172; 1437-160X
• DOI: 10.1007/s00296-018-4007-3

We aim to confirm previous observations among postmenopausal osteoporotic women who received denosumab in terms of densitometric changes. We performed an observational clinical practice scenario study assessing baseline bone mineral density and its change after 2 years of treatment in postmenopausal osteoporotic women. Most of our patients were severe and had previous fracture and had received several treatments before denosumab initiation. We observed a 10.06% (± 3.46) improvement in spine, and a 4.87% (± 4.78) improvement in femoral neck. Our findings are in accordance with other authors that suggest denosumab provides densitometric gain in clinical practice in severe postmenopausal osteoporotic women.